• Pharmacologic management in pregnancy focuses on evaluating efficacy and safety of multiple antihypertensives (methyldopa, labetalol, propranolol, acebutolol, diazoxide) and comparing fetal outcomes, highlighting drug-specific maternal BP control and neonatal risks [1] [9] [15] [3] [20] [14].

• Diagnostic/predictive measurement and risk stratification in obstetric hypertension emphasize standardized BP measurements and specific tests (roll-over test, supine pressor test, standardized BP measurement) to identify risk and early signs of preeclampsia [6] [5] [16] [13].

• Physiological mechanisms underlying pregnancy hypertension highlight plasma volume changes, volume expansion/ contraction, renin-aldosterone dynamics, and angiotensin II fluctuations in normal and preeclamptic pregnancy [4] [12] [8] [18].

• Anticoagulation and hematologic aspects address prophylactic anticoagulation for recurrent hypertension in pregnancy and platelet/coagulation disturbances in preeclampsia, illustrating hematologic involvement in pathophysiology [19] [7].

• Management strategies and historical debates examine diazoxide use in severe preeclampsia/eclampsia, national treatment controversies, and comparisons of antihypertensive approaches (labetalol vs methyldopa), reflecting evolving clinical decision-making [14] [11] [9].